Logo

Amgen Reports sNDA Submission of Otezla (apremilast) to The US FDA's for Adults with Mild to Moderate Plaque Psoriasis

Share this

Amgen Reports sNDA Submission of Otezla (apremilast) to The US FDA's for Adults with Mild to Moderate Plaque Psoriasis

Shots:

  • The sNDA filing is based on P-III ADVANCE trial data- assessing Otezla (30 mg- bid) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis
  • The P-III ADVANCE study results: @16wks.- improvement in its 1EPs of sPGA score; achieve 2EPs i.e- 75% improvement in BSA- change in PASI score
  • Otezla is a selective PDE4 inhibitor- approved therapy for mod. to sev. plaque psoriasis who are candidates for phototherapy or systemic therapy- for active PsA- and for with oral ulcers associated with Behçet’s Disease

 ­ Ref: PRNewswire | Image: Conejo Valley Guide

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions